## Current Status of the Implication of the Clinical Practice Pattern in Hemodialysis Prescription in Regular Hemodialysis Patients in Egypt (Beheira Governorate) Sector (C)

#### **Ehesis**

Submitted for partial fulfillment of master degree
In Internal Medicine

## By

#### **Ibrahim Hamed Shams Eldin Mohamed**

M.B.B.CH.(2009) Faculty of Medicine – Ain Shams University

#### Supervised by

#### **Prof. Dr. Abd EL Basset EL Shaarawy Abd EL Azim**

Professor of Internal Medicine and Nephrology Faculty of Medicine – Ain Shams University

#### **Dr. .Hisham Abo Elil**

Professor assistant of Internal Medicine and Nephrology Faculty of Medicine – Ain Shams University

> Faculty of Medicine Ain Shams University

> > 2015



سورة البقرة الآية: ٣٢



First and foremost, I feel always indebted to **ALLAH**, the Most Kind and the Most Merciful.

I would like to express my sincere thanks and my deepest appreciation to **Prof. Dr. Abd EL Basset EL Shaarawy Abd EL Azim,** Professor of Internal Medicine and Nephrology, Faculty of Medicine Ain Shams University, for his supervision, guidance, valuable advice, helpful directions throughout the whole work.

My deepest gratitude and respect to **Dr.Hisham Abo Elil**, professor Assistant of Internal Medicine and Nephrology, Faculty of Medicine Ain Shams University, for his keen interest, constant support and continuous encouragement during the conduction of this work.

Last but not least, thank you to My Parents and My Family for their support and pushing me forward in every step in my life.

### **List of Contents**

| Subject                                | Page No. |
|--|----------|
| List of Abbreviations                  | i        |
| List of Tables                         | iv       |
| List of Figures                        | vi       |
| Introduction                           | 1        |
| Aim of the Work                        | 3        |
| Review of Literature                   |          |
| Chapter (1): Hemodialysis prescription | 4        |
| Chapter (2): Complications of CKD      | 40       |
| Chapter (3): Hemodialysis in Egypt     | 57       |
| Patients and Methods                   | 66       |
| Results                                | 70       |
| Discussion                             | 97       |
| Summary                                | 109      |
| Conclusions and Recommendations        | 114      |
| References                             | 116      |
| Arabic Summary                         |          |

### **List of Abbreviations**

| Abb.      | Full term  |
|-----------|--|
| ACE       | : Angiotensin-converting enzyme                        |
| ACT       | : Activated clotting time                              |
| ACTs      | : Activated clotting times                             |
| APKD      | : Acute polycystic kidney disease                      |
| AT        | : Anti thrombin  |
| AV        | : Arterio venous                                       |
| BUN       | : Blood urea nitrogen                                  |
| CAPD      | : Continuous ambulatory peritoneal dialysis            |
| CAPD      | : Continuous ambulatory peritoneal dialysis            |
| CKD       | : Chronic kidney disease                               |
| CKD-EPI   | : Chronic Kidney Disease Epidemiology<br>Collaboration |
| CKD-MBD   | : Chronic kidney disease-mineral and bone disorder     |
| CLD       | : Chronic liver diseases                               |
| CVCs      | : Central venous catheters                             |
| CVD       | : Cardiovascular disease                               |
| CVS       | : Cardiovascular system                                |
| DM        | : Diabetes Mellitus                                    |
| DOPPS     | : The Dialysis Outcomes and Practice<br>Patterns Study |
| ECFV      | : Extracellular fluid volume                           |
| eGFR      | : Estimated glomerular filtration rate                 |
| EGIPT-CKD | : Egypt Information, Prevention and Treatment of CKD   |
| EKR       | : Equivalent renal urea clearance                      |
| eKt/V     | : Equilibrated Kt/V                                    |

## List of Abbreviations (Cont...)

| Abb.      | Full term                                  |
|-----------|--|
|           |  |
| EPO       | : Erythropoietin                           |
| ePTFE     | : Expanded polytetrafluoroethylene         |
| Eq        | : Equation                                 |
| ESA       | : Erythropoiesis-stimulating agents        |
| ESAs      | : Erythropoiesis-stimulating agents        |
| ESRD      | : End Stage Renal Disease                  |
| GFR       | : Glomerular filtration rate               |
| HCV       | : Hepatitis C virus                        |
| HD        | : Hemodialysis                             |
| HEMOstudy | : Hemodialysis study                       |
| Hgb       | : Hemoglobin                               |
| HIV       | : Human immunodeficiency virus             |
| HTN       | : Hypertension                             |
| ICU       | : Intensive Care Unit                      |
| IPD       | : Intermittent peritoneal dialysis         |
| IV        | : Intra venous                             |
| K/DIGO    | : Kidney disease improving global outcomes |
| K/DOQI    | : Kidney disease outcome initiative        |
| KoA       | : Mass transfer area coefficient           |
| KUF       | : Ultrafiltration coefficient              |
| LMW       | : Low Molecular Weight                     |
| MDRD      | : Modification of Diet in Renal Disease    |
| МОН       | : Ministry of Health                       |
| MPO       | : Membrane Permeability Outcome            |

## List of Abbreviations (Cont...)

| Abb.         | Full term   |
|--------------|---|
|              |   |
| NKF-DOQI     | : National kidney foundation – disease outcome initiative |
| PRU          | : Percent reduction in urea                               |
| PTH          | : Parathyroid hormone                                     |
| PTX          | : Parathyroidectomy                                       |
| Qb           | : The blood flow rate to the dialyzer                     |
| RDT          | : Renal Denervation Therapy                               |
| rHuEPO       | : Recombinant Human Erythropoietin                        |
| RKF          | : Residual kidney function                                |
| RRT          | : Renal replacement therapy                               |
| SLE          | : Systemic lupus erythematosis                            |
| TAC          | : Time averaged concentration                             |
| TD           | : Time of diaylsis  |
| TMP          | : Trans membrane pressure                                 |
| TSAT         | : Transferrin saturation                                  |
| UF           | : Ultrafiltration   |
| URR          | : Urea reduction ratio                                    |
| <b>VDRAs</b> | : Vitamin D Receptor Activators                           |

### **List of Tables**

| Cable No           | . Eitle  | Page No.        |
|--------------------|--|-----------------|
| Review of          | <u>Literature</u>  |                 |
| <b>Table (1):</b>  | Elements of Hemodialysis Prescription  | on5             |
| <b>Table (2):</b>  | Components of the dialysate  | 15              |
| Results:           |  |                 |
| <b>Table (1):</b>  | Main HD units & number of patients.  | 70              |
| <b>Table (2):</b>  | Baseline characteristic of study popul   | ation71         |
| <b>Table (3):</b>  | Etiology of ESRD & associate morbidities in HD patients  |                 |
| <b>Table (4):</b>  | HD data of the study population  | 78              |
| <b>Table (5):</b>  | Mean monthly Hb levels during 6 mo   | nths 82         |
| <b>Table (6):</b>  | Hb category during 6 months  | 84              |
| <b>Table (7):</b>  | Methods of treatment of anemia duri<br>study period and using of iron and vit                          | •               |
| <b>Table (8):</b>  | Categories of Calcium, Phosphorus a x Po4 product during the last 6 r covered by the study.            | months          |
| <b>Table (9):</b>  | The mean monthly results of serum c and the serum calcium range during t 6 months covered by the study | the last        |
| <b>Table (10):</b> | The mean monthly results of phosphorous and the phosphorous during the last 6 months covered study     | range<br>by the |
| <b>Table (11):</b> | Different types of phosphorus binder by the study population   |                 |

## List of Tables (Cont...)

| Eable No           | v. Eitle  | Page No. |
|--------------------|---|----------|
| <b>Table (12):</b> | Use of vit D analoges and/ or cinacalci           | 92       |
| <b>Table (13):</b> | Complications during HD in the study population   | 93       |
| <b>Table (14):</b> | Criteria of dialyzer used in the study population | 95       |

# **List of Figures**

| Figure No          | . Citle Page No.   |
|--------------------|--|
| Review of          | <u>Literature</u>  |
| Figure (1):        | Nomogram to estimate Kt/V24  |
| Figure (2):        | Changes in blood urea nitrogen measured at different times after dialysis  |
| Figure (3):        | Common arteriovenous fistula sites   |
| Figure (4):        | Arteriovenious grafts  |
| Figure (5):        | Current proportional contribution of the most common causes of end-stage renal disease in Egypt in comparison with two North African countries |
| <b>Results:</b>    |  |
| Figure (1):        | Gender distribution in the study population 72   |
| <b>Figure (2):</b> | Work status in the study population72  |
| Figure (3):        | Dependency status in the study population73  |
| Figure (4):        | Different causes of ESRD in the study population   |
| Figure (5):        | Different comorbidities in the study population  |
| Figure (6):        | Frequency of HD sessions/week in the study population  |
| <b>Figure (7):</b> | Duration of HD sessions in the study population  |
| Figure (8):        | Sponsoring status in the study population80  |